• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Flora Growth Taps Amazon Executive Elshad Garayev As Chief Financial Officer

    7/11/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    • Former Amazon financial operations excellence leader and leading e-commerce platform strategist to assist Flora with financial discipline and reporting
    • Garayev brings 25 years of financial leadership experience at Amazon, Boeing, BP and RPK Capital, and will focus on Flora's global growth initiatives

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today the appointment of Elshad Garayev to serve as Flora's Chief Financial Officer, effective on the business day following the date on which the Company files its mid-year financial results with the Securities and Exchange Commission. Until such time, Mr. Garayev will serve as Vice President of Finance and will work closely with Lee Leiderman, Flora's current CFO, to ensure a smooth transition. Mr. Leiderman will then move into an advisory role with Flora in order to focus on his health and his family.

    Garayev brings over 25 years of experience in finance supporting successful organizations through the development and implementation of accounting and reporting policies as well as building high-performance finance teams. Prior to joining the Flora team, Garayev served in a variety of financial leadership roles at companies such as Amazon, Boeing BP and RPK Capital, managing a diverse array of initiatives at various companies including reporting, accounting, investments, private equity, international operations, mergers and acquisitions, energy services, and manufacturing.

    "I am very excited to join Flora and to become its Chief Financial Officer. As one of the largest cultivators licensed by the federal government of Colombia, their robust portfolio of brands and the future of research in the space, Flora presents a truly amazing opportunity to lead the global cannabis supply chain," said Garayev. "Through financial discipline, transparency and industry-leading reporting practices, I believe Flora will lead the way for the next generation of cannabis companies."

    As CFO, Garayev will focus on financial controls and governance, management of cash position to optimize the utilization of resources across the organization and continued evolution of systems and processes as Flora moves towards quarterly financial reporting. Garayev will also play a critical role in assisting in the execution of Flora's strategy to drive profitable growth and enhance shareholder value.

    "Mr. Garayev is a deeply talented and experienced individual, and I am thrilled to welcome him to the Flora team at this exciting time in the Company's evolution. As Flora seeks to establish itself as a global leader in cannabis, adding someone of his caliber will further strengthen our position," Flora's Chairman and CEO Luis Merchan said. "On behalf of both our executive leadership team and our Board of Directors, I want to personally thank Mr. Leiderman for his commitment and service to Flora through an incredible growth phase for the company. He has played an important role in setting the foundation for our future success and we look forward to continuing to work with him in his new capacity."

    About Flora Growth Corp.

    Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

    Forward-Looking Statements

    This press release contains ‘‘forward-looking statements,'' as defined by federal securities laws. Forward-looking statements reflect Flora's current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled "Risk Factors" in Flora's Annual Report on Form 20-F filed with the SEC on May 9, 2022, as such factors may be updated from time to time in Flora's periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora's filings with the SEC. While forward-looking statements reflect Flora's good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005288/en/

    Get the next $FLGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    SEC Filings

    View All

    Flora Growth Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Flora Growth Corp. (0001790169) (Filer)

    9/29/25 5:18:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Flora Growth Corp.

    424B5 - Flora Growth Corp. (0001790169) (Filer)

    9/29/25 5:10:59 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Flora Growth Corp. (0001790169) (Filer)

    9/23/25 8:28:12 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/17/24 10:17:39 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/11/24 5:43:51 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/6/24 5:25:10 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wolkin Harold

    4 - Flora Growth Corp. (0001790169) (Issuer)

    7/2/25 11:04:19 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Leventhal Manfred

    4 - Flora Growth Corp. (0001790169) (Issuer)

    7/2/25 10:56:28 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Starke Clifford

    4 - Flora Growth Corp. (0001790169) (Issuer)

    7/2/25 10:55:09 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Flora Growth with a new price target

    Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

    11/25/24 8:07:10 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Flora Growth with a new price target

    Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

    10/13/21 9:00:51 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MKM Partners initiated coverage on Flora Growth with a new price target

    MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

    6/23/21 5:36:01 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DeFi Development Corp. Announces Strategic Collaboration with ZeroStack in Treasury Accelerator Deal

    BOCA RATON, FL , Sept. 22, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (NASDAQ:DFDV) (the "Company") the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced a strategic collaboration with ZeroStack, a next-generation Digital Asset Treasury (DAT) focused on accumulating the 0G cryptoasset. 0G is the native token behind the 0G Network, a decentralized AI Layer-1 blockchain that orchestrates hardware resources and software assets to handle AI workloads at scale. As part of the relationship, the Company participated in a private placement transaction by Flora Growth Corp. (NASDAQ:FLGC), which expects to rebrand as ZeroStack, throu

    9/22/25 5:00:00 AM ET
    $DFDV
    $FLGC
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. (FLGC) Announces $401 Million Funding with a $22.88 Million Strategic Investment from Defi Development Corp. (DFDV) to Initiate Groundbreaking AI Zero Gravity ($0G) Coin Treasury Strategy

    $0G, the native cryptocurrency of the distributed AI infrastructure project 0G, will serve as the company's primary reserve assetPartners include DeFi Dev Corp., the first digital asset treasury company to accumulate and compound SolanaFlora to rebrand as ZeroStack and appoint 0G's Co-Founder, Michael Heinrich, to the role of Executive Chairman and Daniel Reis-Faria as CEO$0G is the first-to-market AI-based Digital Asset TreasuryFort Lauderdale, Florida--(Newsfile Corp. - September 19, 2025) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") today announced the pricing of a private investment in public equity offering, positioning the Company to implement a 0G treasury strategy. 0

    9/19/25 6:53:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Closes Acquisition of Australian Vaporizers

    Fort Lauderdale, Florida--(Newsfile Corp. - June 5, 2024) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") has entered into a share purchase agreement (the "Agreement") to acquire of all of the issued and outstanding shares of Australian Vaporizers Pty Limited ("Australian Vaporizers") in exchange for 550,000 Flora common shares, valued at $0.7 million based on the closing price of Flora's common shares on June 3, 2024, subject to working capital adjustments. The transaction closed on June 4, 2024. Australian Vaporizers was founded in 2010 and has become one of the largest online retailers of vaporizers, hardware, and accessories in Australia. It is an online expert for aromathe

    6/5/24 9:20:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    View All

    Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    6/27/23 4:05:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Announces the Appointment of Hussein Rakine as CEO and Member of the Board of Directors

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") a leading cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors (the "Board") accepted the resignation of Luis Merchan as Chairman of the Board and the Company's Chief Executive Officer (CEO). To fill the vacancies created by Mr. Merchan's resignation, the Board has appointed JustCBD founder, Hussein Rakine, as CEO and member of the board of directors. Of the appointment, former-Chairman and CEO, Luis Merchan said, "At Flora we have consistently placed human capital as a critical part of our M&A strategy. That's why today we are honored to have the former foun

    4/18/23 4:05:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CBD Oil Market to Hit Nearly US$137 Billion by 2029

    FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

    8/23/22 8:50:00 AM ET
    $CGC
    $CRON
    $FLGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $FLGC
    Financials

    Live finance-specific insights

    View All

    Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    11/21/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    10/25/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    9/13/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

    SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

    11/14/24 2:24:54 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care